<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865732</url>
  </required_header>
  <id_info>
    <org_study_id>1042-PCDH19-3002</org_study_id>
    <secondary_id>2018-004496-12</secondary_id>
    <nct_id>NCT03865732</nct_id>
  </id_info>
  <brief_title>Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy Followed by Long-term Open-label Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone
      therapy compared to placebo for the treatment of seizures in female children and young adults
      with genetically confirmed PCDH19 gene mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Violet Study is a global, double-blind, placebo-controlled, Phase 3 clinical trial that
      plans to enroll approximately 70 female patients between the ages of 1 and 17 with a
      confirmed disease-related PCDH19 gene variant. Patients will undergo a baseline period before
      being randomized to receive, in addition to their existing anti-seizure treatment, either
      ganaxolone or placebo for 17 weeks. Following the treatment period, all patients that meet
      certain eligibility requirements will have the opportunity to receive ganaxolone in the open
      label phase of the study. The study's primary efficacy endpoint is percent reduction in
      seizures. Secondary outcome measures will include non-seizure-related endpoints to capture
      certain behavioral and sleep disturbances that have been seen in previous clinical studies
      with ganaxolone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The double-blind phase will randomize subjects to adjunctive ganaxolone or placebo at a 1:1 ratio to standard of care.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in 28-day seizure frequency</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Percent change in 28-day seizure frequency during the double-blind treatment period relative to the 12-week prospective baseline period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>50% Primary Seizure Reduction</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Percent of subjects experiencing a greater than or equal to 50% reduction in 28-day primary seizure frequency relative to the 12-week baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive Function</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Behavior rating inventory of executive function during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist - Community</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Aberrant behavior checklist - community during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Sleep Habit Questionnaire</measure>
    <time_frame>End of the double-blind 17 week treatment period</time_frame>
    <description>Children's sleep habit questionnaire during the double-blind treatment period of ganaxolone compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>PCDH19-Related Epilepsy</condition>
  <arm_group>
    <arm_group_label>Ganaxolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo suspension 3x's /day for 17 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>active drug</description>
    <arm_group_label>Ganaxolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>inactive</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for ganaxolone)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Molecular confirmation of a pathogenic or likely pathogenic PCDH19 variant

          -  Failure to control seizures despite 2 or more anti-seizure medications

          -  12 seizures over a 12-week period of primary seizure types prior to screening

          -  On a stable regimen of anti-seizure treatments (Vagus nerve stimulator, ketogenic
             diet, and modified Atkins diet should be unchanged for 3 months prior to screening)

        Exclusion Criteria:

          -  Previous exposure to ganaxolone

          -  &gt; 8 consecutive weeks of seizure freedom during the 12 weeks prior to screening

          -  Concurrent use of strong inducers or inhibitors of CYP3A4/5/7 is not permitted

          -  Use of tetrahydrocannabinol (THC) or non-approved cannabidiol (CBD) is prohibited
             during the double-blind phase

          -  Exposure to any other investigational drug within 30 days or fewer than 5 half-lives
             prior to screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej Gasior, M.D., Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex Aimetti, Ph.D</last_name>
    <phone>484-801-4681</phone>
    <phone_ext>681</phone_ext>
    <email>aaimetti@marinuspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Balderson</last_name>
    <phone>484-801-5638</phone>
    <phone_ext>698</phone_ext>
    <email>jbalderson@marinuspharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Ancona</city>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Verona</city>
        <zip>37124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Heeze</city>
        <zip>5591</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8025</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marinus Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory seizures</keyword>
  <keyword>epilepsy in children</keyword>
  <keyword>seizure disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

